Compare Enveric Biosciences Inc (ENVB) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Vertiv Holdings Co — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Vertiv Holdings Co trades at $247.17 (market cap $94.90B). The key difference: Vertiv Holdings Co is far larger — about 14185.4× Enveric Biosciences Inc's market cap, and Vertiv Holdings Co pays a 0.1% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Vertiv Holdings Co for 39 Days on average.
| ENVB | VRT | |
|---|---|---|
Market Cap | $6.69M | $94.90B |
Volume | 41,141 | 5,469,277 |
Sector | Health | Industrials |
52-Week High | $10.80 | $376.23 |
52-Week Low | $1.27 | $149.83 |
Typical Hold Time | 14 Days | 39 Days |
Enterprise Value | -$1.60M | $95.12B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Vertiv (VRT) trades at $246.49, down 2.63% amid bearish technical signals but maintains strong fundamental momentum with consistent earnings beats and robust AI-driven data center demand. The stock shows elevated valuation multiples (P/E 55.77, P/S 8.42) against impressive profitability (ROE 43.94%, net margin 15.09%), while analyst consensus remains overwhelmingly bullish with a $364.94 price target. Recent news highlights Vertiv's strategic positioning in AI infrastructure cooling solutions.
Outlook remains positive given Vertiv's exposure to the $7.6 trillion AI spending boom (Goldman Sachs, Sep 2026), though risks include potential securities law investigations and competitive pressures. The stock offers growth exposure to data center electrification trends, with Q3 2026 earnings (expected EPS $1.82) serving as the next key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
